Measles Vaccine Coverage and Disease Outbreaks: A Systematic Review of the Early Impact of COVID-19 in Low and Lower-Middle Income Countries

Int J Public Health. 2024 Apr 25:69:1606997. doi: 10.3389/ijph.2024.1606997. eCollection 2024.

Abstract

Objectives: We aimed to evaluate changes to measles-containing vaccine (MCV) provision and subsequent measles disease cases in low- and lower-middle income countries (LICs, LMICs) in relation to the COVID-19 pandemic. Methods: A systematic search was conducted of MEDLINE, OVID EMBASE and PubMed records. Primary quantitative and qualitative research studies published from January 2020 were included if they reported on COVID-19 impact on MCV provision and/or measles outbreak rates within LICs and LMICs. Results: 45 studies were included. The change in MCV1 vaccination coverage in national and international regions ranged -13% to +44.4% from pre-COVID time periods. In local regions, the median MCV1 and overall EPI rate changed by -23.3% and -28.5% respectively. Median MCV2 rate was disproportionally impacted in local areas during COVID-interruption time-periods (-48.2%) with ongoing disruption in early-recovery time-periods (-17.7%). 8.9% of studies reported on vaccination status of confirmed measles cases; from these, 71%-91% had received no MCV dose. Conclusion: MCV vaccination coverage experienced ongoing disruption during the recovery periods after initial COVID-19 disruption. Vaccination in local area datasets notably experienced longer-term disruption compared to nationally reported figures.

Keywords: COVID-19; immunization agenda 2030; inequalities of health; measles; vaccine coverage.

Publication types

  • Systematic Review

MeSH terms

  • COVID-19* / epidemiology
  • COVID-19* / prevention & control
  • Developing Countries*
  • Disease Outbreaks*
  • Humans
  • Measles Vaccine* / administration & dosage
  • Measles* / epidemiology
  • Measles* / prevention & control
  • SARS-CoV-2*
  • Vaccination Coverage* / statistics & numerical data

Substances

  • Measles Vaccine

Grants and funding

The author(s) declare that no financial support was received for the research, authorship, and/or publication of this article.